Catalyst overview
Research summary
This catalyst tracks a Failed discontinued for IPH6501 in Cancer, Non-Hodgkin lymphoma. The expected timing is based on the latest available company guidance and may change.
3/6/24- First patient dosed. Presents Ph1/2 trial update at ASCO '24 on June 3rd. 6/13/25- Preclinical data presentation at EHA'25 on June 14, 2025. 11/12/25:- IPH6501 Ph1/2 B-NHL dose-escalation enrollment complete; clinical data presentation expected in 2026. 03/25/26:- IPH6501 Ph1/2 B-NHL study discontinued after dose escalation; remaining clinical data expected for presentation in 2026.
Verification
Confirm timing and program details against the company announcement or filing.